Dr. Gomella on Novel Prostate Cancer Immunotherapies

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on Novel Prostate Cancer Immunotherapies

Leonard G. Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses novel immunotherapies that are available for prostate cancer. The most exciting immunotherapy currently approved for prostate cancer is Provenge because of its very unique nature. Gomella believes that other immunotherapies, such as ipilimumab, may also move into the prostate cancer field.

View more videos of Leonard G. Gomella, MD.